Google
Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
David Beidler, PhD
Researcher Senior Director, Precision Medicine, Early Clinical Development
Pfizer Inc.
Global Research and Development -
Rare Diseases Research Unit
1 Portland Street
Cambridge, Massachusetts, United States
As the Translational Sciences lead for the phosphodiesterase type 9 inhibitor project, Dr. Beidler contributed to the development, implementation, and analysis of pharmacodynamic biomarkers in the recent phase 1b study in stable sickle cell disease subjects. Dr. Beidler has over 17 years of pharmaceutical industry experience with biomarker/translational pharmacology strategy and clinical operations that span preclinical animal models, natural history/methodology studies, and early (Phase 1/2) clinical trials. Dr. Beidler has also served as the research project team leader and in vivo pharmacology lead on several pain/inflammation project teams that delivered multiple candidate compounds to the clinic.
Representative Publications:
Safety and Tolerability of PF-04447943 across a Clinical Trial Program Including 277 Patients
+myBinderRelated Content
-
A Health Note From Dr. Biree Andemariam, SCDAA Chief Medical OfficerWhat You Need to Know About the Coronavi...
-
Building Access to Care in Adult Sickle Cell Disease: Defining Models of Care, Essential Components, and Economic As...Sickle cell disease (SCD) is the most co...
-
Guy’s and St Thomas’ NHS Foundation TrustOur haemoglobinopathies service sees chi...
-
Patricia Kavanagh, MDPatricia Kavanagh, MD, is an Assistant P...
-
GBT launches ACCEL grants program to improve access to care for people with Sickle cell diseaseGlobal Blood Therapeutics, Inc. (GBT) to...
-
Southeast Alabama Sickle Cell AssociationThe Southeast Alabama Sickle Cell Associ...
-
A Developmental Examination of Pain Among Youth with Sickle Cell DiseaseIntroduction: Sickle cell disease (SCD)...
